Lars Christian Lund

Medicine & Life Sciences

1. Cohort Studies 100%
2. Denmark 71%
3. SARS Virus 70%
4. Severe Acute Respiratory Syndrome 63%
5. Coronavirus 62%
6. Population 46%
7. Prescriptions 37%
8. Venous Thromboembolism 33%
9. Odds Ratio 32%
10. Idiopathic Pulmonary Fibrosis 30%
11. Gout 29%
12. Human Influenza 26%
13. Pharmaceutical Preparations 26%
14. Confidence Intervals 25%
15. Dicloxacillin 25%
16. Angiotensin Receptor Antagonists 25%
17. Mortality 24%
18. Chronic Renal Insufficiency 22%
19. Vaccines 22%
20. Intensive Care Units 21%
21. Serotonin Uptake Inhibitors 20%
22. Febuxostat 19%
23. pimecrolimus 19%
24. Floxacillin 19%
25. Hemorrhage 19%
26. Multimorbidity 19%
27. Hospitalization 19%
28. Anti-Inflammatory Agents 19%
29. Glucagon-Like Peptide-1 Receptor 18%
30. Thioridazine 18%
31. Scandinavian and Nordic Countries 18%
32. Sodium-Glucose Transport Proteins 17%
33. Interrupted Time Series Analysis 17%
34. Registries 17%
35. Incidence 17%
36. Lactulose 17%
37. Equivalence Trials 16%
38. Dipeptidyl-Peptidase IV Inhibitors 16%
39. Propensity Score 16%
40. Restless Legs Syndrome 16%
41. Quetiapine Fumarate 16%
42. Nephrolithiasis 16%
43. Sweden 16%
44. Angiotensin-Converting Enzyme Inhibitors 16%
45. Allopurinol 15%
46. Pandemics 15%
47. Infections 15%
48. Antiemetics 14%
49. Low Molecular Weight Heparin 14%
50. Troponin I 14%